Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
May 4, 2021 12:52 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $84.00 (from $89.00) while maintaining a Sector Perform rating following results.
The analyst commented, "This morning, SAGE reported 1Q21 earnings and guided for $1.7B in cash by end-'21, for a burn rate of... More
SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss
May 4, 2021 7:16 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.
Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More
